Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_41
Snippet: Second, effective dosing after symptom development predicts rapid subsequent elimination of infected. Most current clinical trials are focused primarily on hospitalized patients whereas our results and those from other COVID models suggest that treatment in the days immediately following symptom onset will decrease the duration of detectable viral shedding (24, 25) . Our model also predicts that early treatment will limit the extent of the cytoly.....
Document: Second, effective dosing after symptom development predicts rapid subsequent elimination of infected. Most current clinical trials are focused primarily on hospitalized patients whereas our results and those from other COVID models suggest that treatment in the days immediately following symptom onset will decrease the duration of detectable viral shedding (24, 25) . Our model also predicts that early treatment will limit the extent of the cytolytic immune response required to clear infection. If either of these outcomes are correlates of progression to severe disease and transmission risk, then as with HIV (26), influenza (27) , and Ebola (28), early test and treat is a vital, currently overlooked strategy.
Search related documents:
Co phrase search for related documents- clear infection and day treatment: 1
- clear infection and early treatment: 1
- clear infection and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and COVID model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- clinical trial and current clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and day treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and early test: 1, 2, 3, 4, 5
- clinical trial and early treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical trial and effective dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- clinical trial and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- COVID model and day treatment: 1, 2
- COVID model and early test: 1, 2, 3, 4
- COVID model and early treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- COVID model and effective dose: 1, 2, 3, 4, 5, 6, 7
- COVID model and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- current clinical trial and day treatment: 1
- current clinical trial and early treatment: 1
- current clinical trial and immune response: 1
- day treatment and early test: 1
Co phrase search for related documents, hyperlinks ordered by date